Form 4: Regeneron EVP Sells Shares for Tax Obligations
Insider Transaction Report
Regeneron Pharmaceuticals' EVP of Research, Andrew J. Murphy, disposed of 4,229 shares of common stock to cover tax obligations at a price of $701.51 per share.
Summary
- Andrew J. Murphy, Executive Vice President of Research at Regeneron Pharmaceuticals, Inc. (REGN), reported a transaction on December 9, 2025.
- The transaction involved the disposition of 4,229 shares of Common Stock.
- The shares were disposed of at a price of $701.51 per share.
- The transaction code 'F' indicates the shares were disposed of to the issuer to satisfy tax withholding obligations upon the vesting of restricted stock or similar equity awards.
- Following this transaction, Andrew J. Murphy directly beneficially owns 47,833 shares of Common Stock.
- Additionally, 4,375 shares are indirectly beneficially owned through a 401(k) Plan.
Sentiment
Score: 5
Explanation: The filing reports a routine insider transaction (disposition for tax withholding) which is a neutral event and does not indicate positive or negative sentiment regarding the company's performance or prospects.
Future Outlook
This Form 4 filing reports a past insider transaction and does not contain forward-looking statements or guidance regarding the company's future outlook.
Industry Context
This filing is a routine insider transaction report (Form 4) for a pharmaceutical company executive, reflecting standard equity compensation and tax withholding practices common across publicly traded companies in various industries, including biotechnology and pharmaceuticals. It does not provide specific insights into broader industry trends or competitive positioning.
Stakeholder Impact
- Shareholders: This is a routine, non-discretionary sale for tax purposes and is unlikely to have a significant impact on shareholder perception or the company's stock price.
- Employees: The transaction reflects standard equity compensation practices for executives.
Key Dates
| Date | Description |
|---|---|
| 12/09/2025 | Date of transaction for the disposition of common stock. |
| 12/11/2025 | Date the Form 4 was signed by the reporting person. |
Keywords
Regeneron Pharmaceuticals, REGN, Andrew J. Murphy, Insider Transaction, Form 4, Common Stock, Tax Withholding, Equity Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.